Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 19.9.2022 | EN | Official Journal of the European Union | C 359/68 |

---

Judgment of the General Court of 13 July 2022 — Purasac v EUIPO — Prollenium Medical Technologies (Rejeunesse)

(Case T-543/21) [(1)](#ntr1-C_2022359EN.01006802-E0001)

(EU trade mark - Opposition proceedings - Application for the EU figurative mark Rejeunesse - Earlier EU word mark REVANESSE - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2022/C 359/83)

Language of the case: English

Parties

Applicant: Purasac Co. Ltd (Anyang-si, South Korea) (represented by: P. Lee, lawyer)

Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and J. Crespo Carrillo, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Prollenium Medical Technologies, Inc. (Aurora, Ontario, Canada) (represented by: R. Lyxell, lawyer)

Re:

By its action brought under Article 263 TFEU, the applicant seeks annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 2 July 2021 (Case R 146/2021-4).

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Purasac Co. Ltd to pay the costs. |

---

---

[Top](#document1)